U.S. Medical Equipment Stock News

NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Insulet (PODD) Is Down 15.9% After Cutting 2026 Revenue Guidance on Type 2 Retention Strains

In early August 2026, Insulet Corporation reported second-quarter 2026 results showing revenue of US$801.7 million and net income of US$95 million, with basic and diluted EPS of US$1.37, while also trimming full-year 2026 revenue growth guidance to 21%–23% amid softer U.S. Omnipod demand and type 2 retention issues. Beneath the headline beat, management highlighted weaker-than-expected utilization and retention among U.S. type 2 diabetes users and ongoing product quality and litigation...
NYSE:ICE
NYSE:ICECapital Markets

Is Intercontinental Exchange (ICE) Fairly Priced Or Too Expensive Now?

Intercontinental Exchange stock has delivered a 35.4% gain over the past three years, yet the current checks send a mixed message as the Excess Returns intrinsic value estimate points to a roughly fair price while earnings based multiples lean expensive. Over the last three years, Intercontinental Exchange shares are up 35.4%, which puts recent weakness into context after a tougher past year. Planned expansion in fixed income trading and data, including the agreed MarketAxess acquisition and...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Will Phase III lonvo-z Data and Resumed ATTR Program Change Intellia Therapeutics' (NTLA) Narrative

In the past few days, Intellia Therapeutics reported Q2 2026 results showing a net loss of US$106.63 million, or US$0.80 per share, alongside positive Phase III data for its hereditary angioedema gene-editing therapy lonvo-z and a resumed Phase III program in transthyretin amyloidosis after clinical holds were resolved. These updates both highlight the financial strain of Intellia’s R&D-heavy model and mark important clinical milestones that could reshape its future commercialization path in...
NasdaqGS:ICLR
NasdaqGS:ICLRLife Sciences

Should ICON’s Anthropic AI Collaboration Amid Weaker Q2 Profitability Require Action From ICON (ICLR) Investors?

In late July 2026, ICON plc reported second-quarter 2026 results showing slightly higher sales of US$2,063.49 million but materially lower net income of US$72.58 million year-on-year, while reaffirming full-year revenue guidance of US$7.85–US$8.15 billion. ICON plc also announced a multi-year collaboration with Anthropic to embed Claude’s AI across its Orbis platform and clinical trial workflows, highlighting a push to embed advanced AI into protocol design, site selection, and real-time...
NYSE:IFF
NYSE:IFFChemicals

Why International Flavors & Fragrances (IFF) Is Up 6.4% After New $2.5 Billion Buyback And Guidance

International Flavors & Fragrances Inc. recently reported second-quarter 2026 results showing slightly higher sales of US$1,954 million but a sharp drop in net income to US$50 million, alongside updated full-year guidance reflecting discontinued operations. At the same time, the company unveiled a new US$2.50 billion share repurchase program and affirmed its regular quarterly dividend, underscoring management’s capital return priorities during its portfolio reshaping. We’ll now examine how...
NasdaqGS:PLUS
NasdaqGS:PLUSElectronic

Is ePlus (PLUS) Undervalued Following Strong Bookings And Reiterated 2027 Outlook?

ePlus (PLUS) drew investor attention after reporting modest revenue growth for the fiscal first quarter of 2027, highlighting higher bookings and open orders tied to demand for AI infrastructure, security, cloud, and managed services. See our latest analysis for ePlus. At a share price of $90.35, ePlus has seen short term share price momentum cool after the earnings release, with a 1 day share price return that declined 4.45%. However, the 1 month share price return of 7.78% and 1 year total...
NYSE:AXP
NYSE:AXPConsumer Finance

American Express (AXP) Earnings Beat And Guidance Raise Put Valuation Back In Focus

Why American Express Stock Is Back In Focus After Q2 Results American Express (AXP) has moved back onto many watchlists after reporting stronger second quarter earnings, raising full year revenue guidance, and highlighting heavier marketing and customer engagement spending. For investors, this mix of higher expected revenue, firmer recent profitability, and rising expense concerns creates a fresh moment to reassess what the current stock price implies about future performance. See our latest...